340 related articles for article (PubMed ID: 28556815)
1. The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling.
Domínguez Avila JA; Rodrigo García J; González Aguilar GA; de la Rosa LA
Molecules; 2017 May; 22(6):. PubMed ID: 28556815
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment.
Lee CY
Basic Clin Pharmacol Toxicol; 2016 Mar; 118(3):173-80. PubMed ID: 26551045
[TBL] [Abstract][Full Text] [Related]
3. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia.
Herzberg-Schäfer S; Heni M; Stefan N; Häring HU; Fritsche A
Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():85-90. PubMed ID: 22928568
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of Polyphenols in the Management of Type 2 Diabetes.
Wang Y; Alkhalidy H; Liu D
Molecules; 2021 Jan; 26(3):. PubMed ID: 33572808
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 in health and disease.
Andersen A; Lund A; Knop FK; Vilsbøll T
Nat Rev Endocrinol; 2018 Jul; 14(7):390-403. PubMed ID: 29728598
[TBL] [Abstract][Full Text] [Related]
6. Impact of Lycium barbarum polysaccharide on the expression of glucagon-like peptide 1 in vitro and in vivo.
Zhao C; Zhao H; Zhang CC; Yang XH; Chen K; Xue Y; Li Q; Deng SY; Cai HZ
Int J Biol Macromol; 2023 Jan; 224():908-918. PubMed ID: 36283558
[TBL] [Abstract][Full Text] [Related]
7. Dietary Polyphenols and Gene Expression in Molecular Pathways Associated with Type 2 Diabetes Mellitus: A Review.
Kang GG; Francis N; Hill R; Waters D; Blanchard C; Santhakumar AB
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878222
[TBL] [Abstract][Full Text] [Related]
8. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
9. [The incretin effect and type 2 diabetes].
Quintanilla-García C; Zúñiga-Guajardo S
Rev Med Inst Mex Seguro Soc; 2010; 48(5):509-20. PubMed ID: 21205499
[TBL] [Abstract][Full Text] [Related]
10. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
11. β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.
Seino S; Sugawara K; Yokoi N; Takahashi H
Diabetes Obes Metab; 2017 Sep; 19 Suppl 1():22-29. PubMed ID: 28880474
[TBL] [Abstract][Full Text] [Related]
12. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity.
Liu Z; Stanojevic V; Brindamour LJ; Habener JF
J Endocrinol; 2012 May; 213(2):143-54. PubMed ID: 22414687
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine.
Petersen N; Frimurer TM; Terndrup Pedersen M; Egerod KL; Wewer Albrechtsen NJ; Holst JJ; Grapin-Botton A; Jensen KB; Schwartz TW
Gastroenterology; 2018 Oct; 155(4):1164-1176.e2. PubMed ID: 29935151
[TBL] [Abstract][Full Text] [Related]
14. The antidiabetic therapeutic potential of dietary polyphenols.
Habtemariam S; Varghese GK
Curr Pharm Biotechnol; 2014; 15(4):391-400. PubMed ID: 24938887
[TBL] [Abstract][Full Text] [Related]
15. Physiological functions of poorly absorbed polyphenols via the glucagon-like peptide-1.
Yamashita Y
Biosci Biotechnol Biochem; 2024 Apr; 88(5):493-498. PubMed ID: 38378922
[TBL] [Abstract][Full Text] [Related]
16. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
17. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
Kim TH; Kim MK; Cheong YH; Chae YN; Lee Y; Ka SO; Jung IH; Shin CY; Bae EJ; Son MH
Eur J Pharmacol; 2016 Jan; 771():65-76. PubMed ID: 26621343
[TBL] [Abstract][Full Text] [Related]
18. Polyphenol-rich diets improve glucose metabolism in people at high cardiometabolic risk: a controlled randomised intervention trial.
Bozzetto L; Annuzzi G; Pacini G; Costabile G; Vetrani C; Vitale M; Griffo E; Giacco A; De Natale C; Cocozza S; Della Pepa G; Tura A; Riccardi G; Rivellese AA
Diabetologia; 2015 Jul; 58(7):1551-60. PubMed ID: 25906754
[TBL] [Abstract][Full Text] [Related]
19. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Vilsbøll T; Holst JJ; Knop FK
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
